Corporate & Investor Presentation

Updated: October 28, 2021

Presentation of financial information & forward-looking statements

Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com).

In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, tax outlook, and the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology.

ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.

2 © 2021 ResMed | Corporate & Investor Presentation - updated 28OCT21

Company Overview & Strategy

Who we are / what we do

  • Listed on NYSE & ASX, ~$40B market cap
  • World-leadingdigital health company with over 15.5 million 100% cloud-connectable devices
    • 17.5+ million patients in AirView monitoring ecosystem
    • 110+ million patient accounts in out-of-hospital care network
  • Innovative designer and manufacturer of award-winning devices and cloud-based software solutions
    • Diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions
  • Products and solutions designed to improve patient quality of life, reduce impact of chronic disease, and lower healthcare costs
  • Cloud-basedsoftware solutions and devices designed to provide connected care, improving patient outcomes and efficiencies for healthcare providers
    • Tools that allow fewer people to manage more patients
    • Empower patients to track own health outcomes

4 © 2021 ResMed | Corporate & Investor Presentation - updated 28OCT21

Why invest? - driving long-term shareholder value

Market Dynamics

Growth & Innovation

Financial Results

  • Underpenetrated markets in sleep and COPD
  • Healthcare costs continue to increase
  • Focus on improving patient outcomes
  • Value-basedtechnology solutions
  • Global leader in digital health for sleep and respiratory care
  • Long-termgrowth opportunities
  • 8,500+ patents and designs
  • ~7-8%of revenue invested in R&D
  • Historical revenue and profit growth
  • Recurring revenue
  • Operating excellence program
  • Strong track record of disciplined capital deployment

Total Shareholder Return (NYSE shares as of 9/30/2021):

1-yr 55% ▪ 3-yr 136% ▪ 5-yr 334%

5 © 2021 ResMed | Corporate & Investor Presentation - updated 28OCT21

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

ResMed Inc. published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 20:42:45 UTC.